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Prostate cancer is the most common cancer among men in the United States. For decades, the cornerstone of medical treatment
for advanced prostate cancer has been hormonal therapy, intended to lower testosterone levels, known as Androgen Deprivation
Therapy (ADT). The development of hormone-resistant prostate cancer (now termed castration-resistant prostate cancer:CRPC)
remains the key roadblock in successful long-term management of prostate cancer. New advancements in medical therapy for
prostate cancer have added to the hormonal therapy armamentarium. These new therapeutic agents not only provide a survival
beneﬁt but also show potential for reversing hormonal resistance in metastatic CRPC, and thus redeﬁning hormonally sensitive
disease.
1.Background
Prostate cancer is the 2nd most frequently diagnosed cancer
and the 6th leading cause of death among males worldwide
[1]. In 2011, it is estimated that there will be 240,890 new
cases of prostate cancer and an estimated 33,720 deaths due
to prostate cancer in the USA [2]. A variety of primary
treatment modalities exist to treat localized cancer of the
prostate including surgery, external beam radiation therapy,
brachytherapy, cryosurgery, and High Intensity Focused
Ultrasound(HIFU).However,formetastaticprostatecancer,
the initial treatment has traditionally been hormonal ther-
apy. ADT is eﬀective for 2-3 years on average, and when
hormonal therapy fails, chemotherapy provides a survival
and palliative beneﬁt, at the cost of considerable side eﬀects.
ADT has been given standalone and as an adjunct with other
treatment modalities such as chemotherapy, radiation, and
surgery [3].
2. History of Androgen Deprivation Therapy
in ProstateCancer
Hormonal therapy has long been an integral part of prostate
cancer treatment. In 1811, Scottish surgeon John Hunter
(1728–1793) observed the relationship between prostate
growth and testicular function for the ﬁrst time in his
textbook Practical Observations on the Treatment of Diseases
of the Prostate Gland [4]. Louis AugusteMercier(1811–1882)
of France ﬁrst performed orchiectomy for the treatment of
an enlarged prostate in 1857 [4]. In 1941, Huggins ﬁrst used
estrogen to treat metastatic prostate cancer, which led to a
Nobel prize in 1966, representing one of the ﬁrst successful
systemic therapies for cancer [5].
Similar to breast cancer, prostate cancer is a hormonally
driven solid malignancy. Androgens are the key driver of
growth for both the normal prostate and prostate cancer
cells. Vital in the deﬁnition of castrate-resistant disease
is the recognition of the potential sources of androgen
and approaches aimed at the reduction of their levels.
While we have historically focused on the testicular pro-
duction of androgens, other sites of production include the
adrenal glands and the more recently appreciated source
of intratumoral androgen production. Normally 90–95% of
circulating testosterone is produced by the Leydig cells of the
testes. Another 5–10% of systemic testosterone is synthesized
by the adrenal glands [6]. While production by the testis
is the main source of androgen in prostate cancer prior to
castration, it has now been appreciated that traditionally2 Advances in Urology
deﬁned CRPC is frequently driven by intratumoral androgen
production and synthesis of testosterone from weak adrenal
androgen precursors [7, 8].
Given the multiple sources and associated biosynthesis
pathways of androgen productions, hormonal therapy in
prostate cancer is achieved through multiple mechanisms
with several diﬀerent classes of agents (Table 1).
Though in limited use today, estrogen was initially used
to systematically treat prostate cancer decades ago. Beyond
an agent simply to induce a reduction in testosterone levels,
Serrate et al. reported in 2009 that diethylstilbestrol (DES) is
a reasonable option for salvage therapy for CRPC in patients
previously treated with docetaxel chemotherapy, suggesting
a direct anticancer eﬀect and larger “hormone sensitive”
treatmentwindow[9].Surgicalorchiectomyremainsaviable
option to achieve androgen deprivation to this day [10].
Medical castration can be achieved by using gonadotropin-
releasing hormone (GnRH) agonists such as goserelin,
leuprolide, and histrelin acetate, which induce androgen
deprivation through persistent overstimulation and subse-
quent downregulation at the level of the GnRH receptor
[11,12].GnRHantagonistssuchasdegarelixcanalsodisrupt
androgen production and are a more recent addition to
our medical treatment options [13]. Antiandrogens such
as bicalutamide, nilutamide, and ﬂutamide block the eﬀect
of androgen directly at the androgen receptor, although
the blockade of the androgen receptor is incomplete and
partialagonistpropertiesareobservedwiththeseagents[14].
In contrast, MDV3100 is a new generation antiandrogen
with great aﬃnity for the androgen receptor and no known
agonist eﬀect [15]. Ketoconazole is a nonspeciﬁc inhibitor of
cytochrome P450 enzyme-mediated androgen biosynthesis
[16]. Glucocorticoids such as prednisone have been used
as a palliative agent and likely act by suppressing ACTH
secretion and thus reducing adrenal androgen production
[17]( Figure 1).
Common side eﬀects of hormonal therapy in prostate
cancer treatment include hot ﬂashes, weight gain, gyneco-
mastia, and osteoporosis [18]. Estrogen additionally has
cardiovascular side eﬀects including blood clots [19]a n d
there is also evidence of increased cardiovascular risk with
GnRH agonist in this setting [20]. Side eﬀects of ketocona-
zole include elevated liver transaminases and gastrointestinal
complaints [21].
Hormonal therapy can produce dramatic clinical re-
sponses when initially used to treat advanced prostate
cancer. Unfortunately, prostate cancer patients become re-
sistant to androgen deprivation after about 2-3 years on
average with progressive disease, despite castrate levels
of testosterone [22, 23]. It is hypothesized that despite
reduced androgen levels, one mechanism of resistance is
the production of androgen for growth via intratumoral
and extragonadal pathways. Other mechanisms of hormonal
resistance include upregulation of androgen receptors with
increased sensitivity to androgen at the androgen receptors,
and mutations of androgen receptors itself [24, 25].
3. CurrentAdvancement in Hormonal Therapy
Historically, a serum testosterone level of <50ng/dL
(<1.74nmol/L) has been used as the benchmark to assess
the eﬃciency of hormonal therapy, as comparable to the
level of suppression achieved with surgical castration [26].
Subsequently, disease progression after achieving castration
levels of serum testosterone has been used as the deﬁnition
ofCRPC.Formanyyears,clinicianslackedrigorouslyproven
therapeutic hormonal options for the treatment of prostate
cancer after the development of castration-resistant disease,
with only docetaxel chemotherapy providing a clear survival
beneﬁt in this setting [27, 28]. However, the introduction of
several new hormonal agents has challenged the traditional
deﬁnition of CRPC.
The CYP17 enzyme is a member of the cytochrome
P450 family of enzymes that mediates the biosynthesis of
dehydroepiandrosterone and androstenedione, both precur-
sors of testosterone. Previously, nonselective inhibitors of
C Y P 1 7s u c ha sk e t o c o n a z o l eh a v eb e e nu s e di np r o s t a t e
cancer treatment [29]. In contrast, abiraterone acetate has
been developed to selectively and irreversibly inhibit the
CYP17 enzyme (17α-hydroxylase and C17,20-lyase) [30]
and demonstrated signiﬁcant antitumor activities against
prostate cancer in phase I/II clinical trials [31, 32]. Similar
to abiraterone, TAK-700 (Orteronel) is an investigational
CYP17 inhibitor, that may oﬀer a more precise targeting of
the CYP17 biosynthesis pathway by inhibiting only C17,20-
lyase [33]. Clinical trials of TAK-700 are currently ongoing
[34]. TOK-001 (Galeterone) is another promising investi-
gational CYP17 inhibitor that is currently being evaluated
a phase I/II clinical trial (ARMOR1: Androgen Receptor
Modulation Optimized for Response 1) [35]. Uniquely,
TOK-001 is not only a selective CYP17 (17α-hydroxylase
and C17,20-lyase) inhibitor analogous to abiraterone acetate
but also an androgen receptor modulator [36]. These new
selective CYP17 enzyme inhibitors represent an important
bench-to-bedside advancement, responding to the need
for more potent and speciﬁc inhibitors of extra-gonadal
androgen production.
In a landmark phase III clinical trial from 2011, de
Bono et al. reported that abiraterone acetate plus prednisone
compared to prednisone alone yielded an improved median
overall survival from 10.4 to 14.8 months in patients
with metastatic hormonal-resistant prostate cancer after
docetaxel chemotherapy (P<0.0001). Circulating serum
testosterone levels are reduced to levels of 1-2ng/dL with
abiraterone acetate—much lower than the previous standard
of 50ng/dL used to deﬁne CRPC. In this trial, abiraterone
plus prednisone also showed signiﬁcant improvement in
time to PSA progression (10.2 months versus 6.6 months;
P<0.0001), radiographic progression-free survival (PFS)
(5.6 months versus 3.6 months; P<0.0001), and PSA
response rate (29.1% versus 5.5%; P<0.0001) when
compared to prednisone alone. The immediate side eﬀects
of abiraterone were manageable and primarily related to
elevated mineralocorticoid levels, including hypertension,
ﬂuid retention, and hypokalemia [37].Advances in Urology 3
Table 1: Hormonal therapy in prostate cancer.
Class Existing drugs Investigational drugs
Estrogen Diethylstilbestrol (DES)
GnRH agonists Goserelin, leuprolide, triptorelin, histrelin acetate
GnRH antagonists Degarelix, ∗abarelix
Antiandrogens Bicalutamide, nilutamide, ﬂutamide, ∗∗cyproterone acetate MDV3100, TOK-001
Non-speciﬁc,cytochrome P450 enzyme inhibitors Ketoconazole
Speciﬁc CYP17 inhibitors Abiraterone acetate TAK-700, TOK-001
Glucocorticoids Prednisone, Dexamethasone, others
∗Abarelix use in the United States was previously limited to a registry program and it is not actively marketed in the United States currently.
∗∗Cyproterone acetate is not currently FDA approved for the treatment of prostate cancer in the United States.
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Figure 1: Hormonal therapy in prostate cancer. Physiologically relevant androgens for prostate cancer originate from three sources: the
testicle, adrenal glands, and via intratumoral production. The sites of activity of clinically relevant hormonal therapies are illustrated here,
with new and investigational treatments indicated in red.
While androgen receptor signaling remains an important
pathway of growth in CRPC, the currently available antian-
drogens have not been able to completely block androgen
receptor signaling [38]. In another area of bench-to-bedside
advancement, a new generation antiandrogen (MDV3100)
is now in clinical development with encouraging results.
Unlikecurrentlyavailableantiandrogens,MDV3100isapure
androgen receptor antagonist without agonist activity. It is
diﬀerentiated from the current antiandrogens by its more
eﬀective blocking of androgen receptor nuclear translocation
and coactivator recruitment of the ligand-receptor complex
[39]. In a multicenter, phase I/II study involving 140 patients
from 2010, Scher et al. reported that MDV3100 showed
antitumor activities in patients with metastatic CRPC, in-
cluding decreases in serum prostate-speciﬁc antigen of 50%
or more in 78 of 140 (56%) patients, responses in soft tissue
in 13 of 59 (22%) patients, stabilized bone disease in 61
of 109 (56%) patients, and conversion from unfavorable to
favorable circulating tumor cell counts in 25 of 51 (49%)
patients [40]. Side eﬀects include fatigue, which generally
resolved with dose reduction [40] and seizure at higher doses
[41]. Phase III studies examining the eﬃcacy of MDV31004 Advances in Urology
both before and after docetaxel chemotherapy in men with
CRPC are underway [34, 42].
GnRH plays a key role in the androgen axis. GnRH
agonists have been used to achieve medical castration in
prostate cancer for decades. Unlike the original GnRH recep-
tor agonists, the recently approved degarelix acts as a direct
GnRH antagonist, suppressing LH release without the iniital
androgen ﬂare and potential exacerbation of symptoms
noted with GnRH receptor agonists [43]. GnRH antagonists
such as degarelix also have a faster onset of action with less
delay in the suppression of testosterone to castrate levels
than GnRH agonists [44]. In a phase III clinical trial from
2008, Klotz et al. reported that when compared to leuprolide
after a 1-year treatment period, degarelix was not inferior to
leuprolideatmaintaininglowtestosteronelevels.Inaddition,
degarelix achieved testosterone and PSA suppression more
rapidly than leuprolide with no need for antiandrogen
supplements to prevent the initial clinical ﬂare. Manageable
side eﬀects of degarelix include ﬂushing, injection-site pain,
weight gain, and increased serum transaminase levels [45]. It
is important to highlight that when compared to leuprolide,
degarelix might oﬀer better suppression of serum alkaline
phosphatase (S-ALP) level and more prolonged control
of skeletal metastases [46]. Furthermore, though degarelix
and leuprolide both act on the GnRH receptor, reports of
response to degarelix after previous resistance to GnRH
agonist therapy with leuprolide have appeared [47], also
potentially complicating our traditional deﬁnition of CRPC.
4. Discussion
The phase III, landmark ﬁndings of the abiraterone acetate
study by de Bono et al. have drawn into question our
traditional deﬁnition of CRPC. Previously, phase I/II clinical
trials of the CYP17 inhibitor abiraterone acetate demon-
strated clinical activity in CRPC [31, 32]. This phase III
study demonstrates a clear survival beneﬁt from additional
hormonal manipulation in a prostate cancer population
previously described as hormone refractory. Clearly, simply
deﬁning CRPC as progressive disease with a serum testos-
terone level of less than 50ng/dL is no longer adequate. The
ﬁndings of de Bono et al. are consistent with other inves-
tigations showing ongoing androgen-related activity in the
post-chemotherapy setting. Going forward, the deﬁnition of
hormone-sensitive prostate cancer will need to incorporate
the use of a potent CYP17 enzyme inhibitor such as abi-
raterone acetate. Accordingly, a much lower level of systemic
testosterone, beyond the traditional 50ng/dL benchmark
and closer to the 1-2ng/dL level, must be targeted to
achieve “complete” androgen deprivation. New investiga-
tional agents such as TAK-700 and TOK-001 represent
addition agents in this class of CYP17 inhibitors, currently
undergoing clinical testing in CRPC [33, 35]. Additionally,
the use of new generation antiandrogens, such as MDV3100,
must also be integrated into our deﬁnition of hormone-
sensitive prostate cancer. The available clinical trial data with
this drug, although early and limited, suggests substantial
activity in a traditionally deﬁned CRPC population [48].
It is exciting to envision a future with additional clinical
gainsfromtheearlieruseofpotentCYP17enzymeinhibitors
in the course of disease treatment or with combination
therapy of abiraterone acetate and other newer agents such
as MDV3100. As a general principle, selective pressures from
cancer therapy typically yield resistant strains of disease
with progressively more aggressive features. Currently, we
do not have a good understanding of the phenotypes of
advanced prostate cancer that may emerge after early
treatment with much more potent hormonal therapies such
as MDV3100 and abiraterone acetate. Many unanswered
questions remain about the prostate cancer phenotype that
will emerge after early use of CYP17 inhibition in terms of
robustness, virulence, speed of disease progression, and the
responsiveness to cytotoxic chemotherapy.
Since John Hunter ﬁrst described the link between the
testis and the prostate over 200 years ago, hormonal therapy
remains one of the mainstays of advanced prostate cancer
treatment. After initial response, metastatic prostate cancer
typicallybecomesresistanttostandardandrogendeprivation
therapy. Improved survival in this setting has been demon-
strated in recent clinical trials involving new agents such
as the CYP17 inhibitor abiraterone acetate and the antian-
drogen MDV3100, showing that CRPC remains hormonally
driven even after treatment with docetaxel chemotherapy,
challenging our traditional deﬁnition of hormone-sensitive
disease.Eventhoughthesurvivalbeneﬁtisincrementalinthe
phase III study of very advanced CRPC patients, a threshold
has clearly been crossed in deﬁning and treating advanced
prostate cancer.
With so many new agents for advanced prostate can-
cer, individual patient characteristics may become very
important in the selection and monitoring of therapy. The
advantages of Degarelix over previous GnRH agonists may
be incremental for most CRPC patients, but the quicker fall
in testosterone may be very important to those with critical
metastatic or painful lesions such as spinal metastases or
near-total urinary obstruction. Likewise, the combination
of “complete” androgen deprivation with abiraterone along
with the required safety medication of low-dose gluco-
corticoid may induce more bone disease via worsening
osteoporosis. Men with preexisting bone mineral density
loss in this setting may require careful monitoring of the
bone mineral density and the use of early bisphosphonates.
In this same light, the side eﬀect proﬁle of a potent
antiandrogen, which will not lower circulating androgen
levels by itself, may become an important consideration if
monotherapy with such agents becomes accepted. Further-
more, much like breast cancer is classiﬁed and treated based
on hormonal receptor characterization today, we believe
that advanced prostate cancer may one day also be treated
based on molecular assessment. As more is known about
the molecular characterization of advanced prostate cancer,
it will be imperative to develop more personalized hormonal
therapy for individual patients. Taken together, one of the
major challenges moving forward will be the personalized
application of these new agents in those with advanced
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